(19)
(11) EP 4 072 552 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
15.01.2025 Bulletin 2025/03

(45) Mention of the grant of the patent:
18.12.2024 Bulletin 2024/51

(21) Application number: 20828088.3

(22) Date of filing: 11.12.2020
(51) International Patent Classification (IPC): 
A61K 31/4745(2006.01)
A61K 47/34(2017.01)
A61K 45/06(2006.01)
A61K 31/495(2006.01)
 A61K 9/00(2006.01)
A61P 35/00(2006.01)
A61K 31/47(2006.01)
(52) Cooperative Patent Classification (CPC):
A61K 31/4745; A61K 9/0085; A61K 47/34; A61P 35/00; A61K 45/06; A61K 31/47; A61K 31/495
 
C-Sets:
  1. A61K 31/4745, A61K 2300/00;
  2. A61K 31/47, A61K 2300/00;
  3. A61K 31/495, A61K 2300/00;
(86) International application number:
PCT/GB2020/053185
(87) International publication number:
WO 2021/116701 (17.06.2021 Gazette 2021/24)

(54)

CHEMOTHERAPEUTIC DRUG IMPLANT

CHEMOTHERAPEUTIKUMIMPLANTAT

IMPLANT DE MEDICAMENT CHIMIOTHERAPIQUE

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30) Priority: 12.12.2019 GB 201918300

(43) Date of publication of application:
19.10.2022 Bulletin 2022/42

(73) Proprietor: CRISM THERAPEUTICS LTD
London W1B 4BT (GB)

(72) Inventor:
  • MCCONVILLE, Christopher
    Birmingham West Midlands B23 6HP (GB)

(74) Representative: HGF 
HGF Limited 1 City Walk
Leeds LS11 9DX
Leeds LS11 9DX (GB)


(56) References cited: : 
EP-A1- 1 985 286
WO-A1-2016/030748
 WO-A1-2014/059022
WO-A2-2006/027567
   
     
    Remarks:
    The file contains technical information submitted after the application was filed and not included in this specification
     
    Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).